03217nam a2200301 4500 ESSALUD ta t pe ||||| |||| 00| 0 spa d BMG spa Barratt, Jonathan 53827 Iptacopan in IgA nephropathy — Final 24-month data páginas: 465-477 Background: Overactivation of the alternative complement pathway contributes to IgA nephropathy and glomerular inflammation. In the 9-month interim analysis of this phase 3 trial, iptacopan, a complement factor B inhibitor, led to a significant reduction of 38.3% in the 24-hour urinary protein-to-creatinine ratio as compared with placebo and had an acceptable safety profile. Methods: In this phase 3 trial, we enrolled adults who had IgA nephropathy, an estimated glomerular filtration rate (eGFR) of at least 30 ml per minute per 1.73 m2 of body-surface area, and a 24-hour urinary protein-to-creatinine ratio of 1 or higher (with protein and creatinine both measured in grams) despite supportive care. Patients were randomly assigned, in a 1:1 ratio, to receive oral iptacopan (200 mg) or placebo twice daily. The primary end point for the final analysis was the annualized total eGFR slope as estimated over a 24-month period. Secondary end points included a composite kidney-failure end point (i.e., a sustained decline in eGFR of ≥30%, a sustained eGFR of <15 ml per minute per 1.73 m2, the initiation of maintenance dialysis, receipt of kidney transplant, or death from kidney failure), assessed in a time-to-event analysis. Safety was also assessed. Results: Among 477 patients included in the final analysis, 238 had been randomly assigned to iptacopan and 239 to placebo. The annualized total eGFR slope was −3.10 ml per minute per 1.73 m2 per year with iptacopan, as compared with −6.12 ml per minute per 1.73 m2 per year with placebo (difference, 3.02 ml per minute per 1.73 m2 per year; 95% confidence interval [CI], 2.02 to 4.01; adjusted P<0.001). A composite kidney-failure end-point event occurred in 21.4% of the patients in the iptacopan group, as compared with 33.5% of those in the placebo group (hazard ratio, 0.57; 95% CI, 0.40 to 0.81; adjusted P=0.003). The incidence of adverse events was 87.0% in the iptacopan group and 89.1% in the placebo group. Serious adverse events occurred in 12.2% of the patients who received iptacopan and in 11.7% of those who received placebo, and serious infections in 6.7% and 2.1%, respectively. No deaths occurred. Conclusions: Iptacopan therapy led to a significantly slower decline in kidney function than placebo ALERGIA 7055 INMUNOLOGÍA 34121 ENFERMEDAD RENAL CRÓNICA 32213 MEDICINA CLÍNICA 33681 GASTROENTEROLOGÍA 12562 NEFROLOGÍA 13133 Eren, Necmi 53828 Kashihara, Naoki 53829 Maes, Bart 53830 Rizk, Dana V. 53831 Rovin, Brad 53832 22717 22638 Massachusetts NEJM Group NEJM005 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-07-31 SQB 22753 22753